Xoma will be announcing the upcoming POC#3 trial details any day now followed up by the Servier Gevokizumab Phase III cardio trial sometime in Q4/2012. The Acne Phase II trial data is expected in late Q4 followed up with the ACEON Phase III hypertension trial data in Q1/13.
Anyone who’s been following Xoma is also aware of the additional efforts this company is working on that could trigger further investor excitement.
With positive momentum driving the share price this is NOT a good time to be short.
yesterday an article in Nature mag claims that IL-1 blocking is effective in RA. If you search Xoma in the mag, a 9/27 article comes up that says ilaris was successful in a RA trial. Gevo has the same mode of action. Proof that the Arthritis of the hand trial Xoma is running will be successful. There are 4 million people in the US with this disease. Surely Gevokizumab sales will easily eclipse a billion a year.
With the P3 Behcet in europe starting you know Xoma and Servier already know the effectivness is a given since the Behcet trials in South Korea and Turkey are almost over. You sure would not start another P3 trial if the current one was not going well. I think Xoma and Servier are making a name for Gevo all over the world. Giving people their sight back is amazing.